{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:12:27Z","timestamp":1788426747093,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92569202"],"award-info":[{"award-number":["92569202"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273692"],"award-info":[{"award-number":["82273692"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jinf.2026.106799","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:31:00Z","timestamp":1781800260000},"page":"106799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Convergent neutralizing antibodies to SARS-CoV-2 variants over 2.5 years after BA.5\/BF.7 breakthrough infection"],"prefix":"10.1016","volume":"93","author":[{"given":"Meng","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Xia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Dong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Man","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Le","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Er-Hei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8105-462X","authenticated-orcid":false,"given":"Mai-Juan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2026.106799_bib1","unstructured":"World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 20 March 2020. 2020. (https:\/\/www.who.int\/news-room\/speeches\/item\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19\u201312-february-2021)."},{"issue":"3","key":"10.1016\/j.jinf.2026.106799_bib2","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jinf.2026.106799_bib3","doi-asserted-by":"crossref","first-page":"105634","DOI":"10.1016\/j.ebiom.2025.105634","article-title":"SARS-CoV-2 serotyping based on spike antigenicity and its implications for host immune evasion","volume":"114","author":"Ruan","year":"2025","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.jinf.2026.106799_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"10.1016\/j.jinf.2026.106799_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114387","article-title":"Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection","volume":"43","author":"Jiang","year":"2024","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.jinf.2026.106799_bib6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","article-title":"SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase","volume":"57","author":"Srivastava","year":"2024","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.jinf.2026.106799_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115557","article-title":"Phenotypic heterogeneity defines B cell responses to repeated SARS-CoV-2 exposures through vaccination and infection","volume":"44","author":"Kardava","year":"2025","journal-title":"Cell Rep"},{"issue":"10377","key":"10.1016\/j.jinf.2026.106799_bib8","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0140-6736(23)00129-0","article-title":"Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis","volume":"401","author":"Pan","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jinf.2026.106799_bib9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41591-023-02212-y","article-title":"Estimating the transmission dynamics of SARS-CoV-2 Omicron BF.7 in Beijing after adjustment of the zero-COVID policy in November-December 2022","volume":"29","author":"Leung","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jinf.2026.106799_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2169197","article-title":"Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai","volume":"12","author":"Wu","year":"2023","journal-title":"Emerg Microbes Infect"},{"issue":"3","key":"10.1016\/j.jinf.2026.106799_bib11","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41591-023-02241-7","article-title":"Determinants of COVID-19 vaccination status and hesitancy among older adults in China","volume":"29","author":"Wang","year":"2023","journal-title":"Nat Med"},{"issue":"48","key":"10.1016\/j.jinf.2026.106799_bib12","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2514157122","article-title":"China's post-zero-COVID Omicron wave: A Bayesian analysis","volume":"122","author":"Cai","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.jinf.2026.106799_bib13","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1038\/s41467-023-40940-4","article-title":"Effects of public-health measures for zeroing out different SARS-CoV-2 variants","volume":"14","author":"Ge","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jinf.2026.106799_bib14","unstructured":"China Center for Disease Control and Prevention. The National Situation of COVID-19 Infections-November 2025. 2025. (https:\/\/www.chinacdc.cn\/jksj\/xgbdyq\/202512\/t20251205_313996.html)."},{"issue":"1","key":"10.1016\/j.jinf.2026.106799_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-025-02132-y","article-title":"Neutralizing antibody responses to three XBB protein vaccines in older adults","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jinf.2026.106799_bib16","first-page":"101040","article-title":"Seroprevalence of SARS-CoV-2 neutralising antibodies and cross-reactivity to JN.1 one year after the BA.5\/BF.7 wave in China","volume":"44","author":"Song","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"10.1016\/j.jinf.2026.106799_bib17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-025-02437-y","article-title":"Neutralizing antibody durability and SARS-CoV-2 infection in older adults six months after XBB-containing vaccine booster","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.jinf.2026.106799_bib18","first-page":"175","article-title":"A note on some points of calculation method of LD50 by Reed and Muench","volume":"20","author":"Matumoto","year":"1949","journal-title":"Jpn J Exp Med"},{"issue":"11","key":"10.1016\/j.jinf.2026.106799_bib19","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1038\/s41596-020-0394-5","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay","volume":"15","author":"Nie","year":"2020","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jinf.2026.106799_bib20","unstructured":"Riehmann P, Hanfler M, Froehlich B, editors. Interactive Sankey diagrams. IEEE Symposium on Information Visualization, 2005 INFOVIS 2005; 2005 23-25 Oct. 2005."},{"key":"10.1016\/j.jinf.2026.106799_bib21","first-page":"218","article-title":"Exploring Patient Path Through Sankey Diagram: A Proof of Concept","volume":"270","author":"Lamer","year":"2020","journal-title":"Stud Health Technol Inform"},{"key":"10.1016\/j.jinf.2026.106799_bib22","unstructured":"Raivo Kolde. pheatmap Pretty Heatmaps: 2025. \u3008https:\/\/cran.r-project.org\/package=pheatmap\u3009."},{"key":"10.1016\/j.jinf.2026.106799_bib23","doi-asserted-by":"crossref","first-page":"e2286","DOI":"10.7717\/peerj-cs.2286","article-title":"Comprehensive analysis of clustering algorithms: exploring limitations and innovative solutions","volume":"10","author":"Wani","year":"2024","journal-title":"PeerJ Comput Sci"},{"key":"10.1016\/j.jinf.2026.106799_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1109\/RBME.2010.2083647","article-title":"2nd. Clustering algorithms in biomedical research: a review","volume":"3","author":"Xu","year":"2010","journal-title":"IEEE Rev Biomed Eng"},{"issue":"5682","key":"10.1016\/j.jinf.2026.106799_bib25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1126\/science.1097211","article-title":"Mapping the antigenic and genetic evolution of influenza virus","volume":"305","author":"Smith","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jinf.2026.106799_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105438","article-title":"Longitudinal effects of SARS-CoV-2 breakthrough infection on imprinting of neutralizing antibody responses","volume":"110","author":"Einhauser","year":"2024","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.jinf.2026.106799_bib27","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.immuni.2024.02.017","article-title":"Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants","volume":"57","author":"Johnston","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.jinf.2026.106799_bib28","doi-asserted-by":"crossref","first-page":"107198","DOI":"10.1016\/j.ijid.2024.107198","article-title":"Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations","volume":"147","author":"Song","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2026.106799_bib29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41392-025-02319-3","article-title":"Dynamics of neutralizing antibodies against COVID-19 Omicron subvariants following breakthrough infection in southwest China between December 2022 and April 2024","volume":"10","author":"He","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"10.1016\/j.jinf.2026.106799_bib30","doi-asserted-by":"crossref","first-page":"324","DOI":"10.46234\/ccdcw2024.061","article-title":"Genomic Surveillance for SARS-CoV-2 Variants: Dominance of XBB Replacement - China, January-June 2023","volume":"6","author":"Feng","year":"2024","journal-title":"China CDC Wkly"},{"issue":"10","key":"10.1016\/j.jinf.2026.106799_bib31","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/S1473-3099(23)00555-8","article-title":"Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6","volume":"23","author":"Wang","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.jinf.2026.106799_bib32","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1473-3099(23)00010-5","article-title":"ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5","volume":"23","author":"Yue","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"8047","key":"10.1016\/j.jinf.2026.106799_bib33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41586-024-08315-x","article-title":"Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1","volume":"637","author":"Jian","year":"2025","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jinf.2026.106799_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41467-023-35949-8","article-title":"Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2","volume":"14","author":"Huang","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.jinf.2026.106799_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114567","article-title":"Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1","volume":"43","author":"Muik","year":"2024","journal-title":"Cell Rep"},{"issue":"7993","key":"10.1016\/j.jinf.2026.106799_bib36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41586-023-06753-7","article-title":"Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting","volume":"625","author":"Yisimayi","year":"2024","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.jinf.2026.106799_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110561","article-title":"Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting","volume":"38","author":"Hauser","year":"2022","journal-title":"Cell Rep"},{"issue":"8","key":"10.1016\/j.jinf.2026.106799_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109604","article-title":"Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals","volume":"36","author":"Chen","year":"2021","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.jinf.2026.106799_bib39","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s43856-025-00898-4","article-title":"Immune imprinting and vaccine interval determine antibody responses to monovalent XBB.1.5 COVID-19 vaccination","volume":"5","author":"Wrynla","year":"2025","journal-title":"Commun Med (Lond)"},{"issue":"1","key":"10.1016\/j.jinf.2026.106799_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.chom.2023.11.012","article-title":"Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster","volume":"32","author":"Wang","year":"2024","journal-title":"Cell Host Microbe"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326001246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326001246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T08:15:31Z","timestamp":1788423331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445326001246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0163445326001246"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106799","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Convergent neutralizing antibodies to SARS-CoV-2 variants over 2.5 years after BA.5\/BF.7 breakthrough infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106799"}}